Pathophysiology of RAGE in inflammatory diseases

Hanbing Dong, Yue Zhang, Yu Huang and Hui Deng*

Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, China

The receptor for advanced glycation end products (RAGE) is a non-specific multi-ligand pattern recognition receptor capable of binding to a range of structurally diverse ligands, expressed on a variety of cell types, and performing different functions. The ligand–RAGE axis can trigger a range of signaling events that are associated with diabetes and its complications, neurological disorders, cancer, inflammation and other diseases. Since RAGE is involved in the pathophysiological processes of many diseases, targeting RAGE may be an effective strategy to block RAGE signaling.

KEYWORDS
RAGE, ligands, signaling, inflammatory diseases, RAGE inhibitors

1 Introduction

The receptor for advanced glycation end products (RAGE) is a multi-ligand receptor, a member of the immunoglobulin (Ig) superfamily, whose structure can be divided into three parts: the extracellular segment, the transmembrane segment and the intracellular segment. The extracellular segment of RAGE is the ligand binding site and consists of three immunoglobulin domains, including the V-type, C1-type and C2-type domains (1). The extracellular segment is followed by a transmembrane segment and a short, highly charged intracellular segment, which is primarily associated with signaling (2, 3). The cytoplasmic tail region of RAGE (ctRAGE) binds to diaphanous-related formin 1 (DIAPH+1), toll-interleukin 1 receptor domain containing adaptor protein (TIRAP) and other bridging proteins, which in turn activate downstream signaling (4–6). RAGE is expressed on a variety of cell types, such as vascular endothelial cells, immune cells, monocytes/macrophages, neurons, cardiomyocytes, adipocytes, glomerular epithelial cells, podocytes and alveolar epithelial cells (7–11).

The human RAGE gene is located on the major histocompatibility complex locus in the class III region of chromosome 6p21.3, a gene-dense region containing many inflammatory genes (12). To date, multiple genetic variant forms of the RAGE gene have been identified, including -429T/C (rs1800625), -374T/A (rs1800624), and G82S (rs2070600), which may affect RAGE expression or function. The RAGE -429 T/C and -374 T/A genotypes have been shown to have an effect on transcriptional activity (13). The RAGE G82S genotype upregulates the binding of S100 proteins to RAGE (14).
In addition to cell surface RAGE, there are two known forms of soluble RAGE. The first type is sRAGE, which consists of extracellular ligand-binding structural domains that are proteolytically cleaved by matrix metalloproteinases (MMPs), integrin α(IIgα), and metalloproteinase (ADAM)-10 pairs of full-length RAGE bound to the cell membrane (fRAGE). The second type is endogenously secreted RAGE (esRAGE), which is a splice variant that is actively secreted by the cell. sRAGE and esRAGE both bind RAGE ligands, preventing them from interacting with fRAGE and acting as ligand inhibitors in humans (15, 16).

Cell surface RAGE and its ligand interactions are involved in cellular cascade responses leading to inflammatory phenotypes in vitro and in vivo, and are involved in the pathophysiology of a variety of diseases. The function of nuclear RAGE has recently been explored and it was found that, unlike the function of surface RAGE, nuclear RAGE may be essential for DNA damage repair, the mechanism of which and the cell types involved are unclear (17, 18). It follows that RAGE has a dual function: as a cell surface receptor, it is part of the pro-inflammatory response, and in the nucleus, it is part of DNA repair. This review focuses on cell surface RAGE and its involvement in the inflammatory response.

2 RAGE Ligands

RAGE recognizes a variety of ligands, including endogenous and food-derived advanced glycation end products (AGEs), high mobility group box 1 (HMGB1), S100 proteins, lysophosphatidic acid (LPA), amyloid beta (Aβ), phosphatidylserine (PS), complement protein C1q, islet amyloid polypeptide (IAPP), etc (1, 19–24).

2.1 AGEs

RAGE was first isolated from bovine lung in 1992 and named for its ability to act as a receptor for AGEs (25). AGEs are a group of irreversible products produced by the non-enzymatic glycosylation and oxidation of proteins, nucleic acids and lipids, a process known as the Maillard reaction (26). AGEs have two sources in the body, one is the synthesis of excess sugar and protein in the body, and the other is exogenous intake, mainly dietary intake, and AGEs have also been found in cigarette smoke (27). Methylglyoxal (MGO), the main precursor of AGEs, is a highly reactive dicarbonyl compound formed mainly as a by-product of glycolysis. Under physiological conditions, MGO is detoxified to D-lactate by the glyoxalase system, and glyoxalase I (GLO1) serves as the key enzyme for this process (28). More than 20 different AGEs have been identified in human blood and tissues as well as in food, including carboxymethyl lysine (CML), carboxyethyl lysine (CEL), pyrroline, pentosidine and methylglyoxal-lysine dimer (MOLD) (29, 30). Many studies have reported an association between AGEs and various chronic inflammatory diseases, and the accumulation of AGEs in vivo is associated with various pathophysiological conditions such as diabetes (31), cardiovascular diseases (32), neurological diseases (33) and cancer (34). AGEs induce pathological processes through three main mechanisms: first, by altering the structural features of proteins through the formation of crosslinks; second, by interacting with their receptor RAGE, which activates downstream signaling pathways leading to increased production of reactive oxygen species and inflammatory cytokines; and third, by intracellular accumulation (35).

2.2 HMGB1

HMGB1 was the first non-AGEs ligand identified to bind to RAGE (36). It was first extracted from calf thymus chromatin in 1973 and was named for its high mobility in gel electrophoresis (37). HMGB1 is an evolutionarily conserved nuclear protein consisting of three functional regions: two N-terminal DNA-binding structural domains (A-box and B-box) and an acidic C-terminal structural domain, of which the HMGB1 B-box is associated with the release of cytokines and is the functional structural domain that elicits the inflammatory response (38). HMGB1 is widely distributed in brain, heart, lung, liver, spleen, kidney, lymph and other tissues, and can be detected in the nucleus, cytoplasm and extracellular (39). In different parts of the cell, HMGB1 has different functions. In the nucleus, HMGB1 acts as a DNA chaperone, participating in DNA repair and maintaining chromosome stability; in the cytoplasm, HMGB1 interacts with Beclin-1 to induce autophagy; in the extracellular, HMGB1 is associated with inflammatory responses and immunosuppression (40). HMGB1 is mainly located in the nucleus at rest, however, under conditions of cell activation, stress, and injury, HMGB1 can enter the cytoplasm through post-translational modifications such as acetylation, poly ADP-ribosylation, and eventually be released into the extracellular space during cell activation and apoptosis (40–42). Extracellular HMGB1 can interact with RAGE, Toll-like receptors and receptors for cytoplasmic DNA/RNA sensors mediating inflammation to promote immune cell maturation, activation and cytokine production and thus participate in a variety of pathological processes (43, 44).

2.3 S100 proteins

The S100 family is one of the largest subfamilies of calcium-binding proteins, and more than 20 members of this family have
been identified to date, including S100A1-S100A18, S100B, S100G, S100P and S100Z (45). They share a high degree of sequence and structural similarity, where each protein is encoded by a single gene. Of the more than 20 human S100 genes, the group A S100 protein is located within chromosome 1q21, with the other members (S100B, S100G, S100P and S100Z) mapping to different regions (46). In cells, most S100 proteins exist as homodimers, while a few form heterodimers, trimers and tetramers. They can exist as monomers under specific conditions, but the dimers exhibit important biological functions (47–49). The S100 protein family acts as a Ca2+ sensor and regulates many activities inside and outside the cell in a Ca2+ dependent manner (50). Inside cells, S100 proteins undergo conformational changes by binding to Ca2+, exposing binding sites to target proteins and producing biological effects, such as regulation of gene expression, enzyme activation, cell cycle, cytoskeleton composition, cytosolic Ca2+ concentration and inflammatory responses. Certain members of the S100 protein family are released extracellularly in an autocrine or paracrine manner and activate multiple inflammatory signaling pathways by interacting with a variety of cell surface receptors, including RAGE, G protein-coupled receptors, Toll-like receptor 4 (TLR4), scavenger receptors, and fibroblast growth factor receptor 1 (FGFR1), ultimately activating transcription of pro-inflammatory factors, including TNF-α, IL-1β, IL-6, and IL-8, as well as leading to reactive oxygen species production and apoptosis (47). The S100 proteins found to bind to RAGE include S100A1, S100A2, S100A4-9, S100A11, S100A12, S100A13, S100B and S100P (48, 51). Studies have shown that S100 protein expression is significantly altered in many tumors, neurodegenerative diseases, inflammatory and autoimmune diseases and can be used as a marker for these diseases (20, 52, 53).

2.4 LPA

LPA is a small, naturally occurring glycerophospholipid that consists of a glycerol backbone with an ester-linked acyl chain and a phosphate group. LPA is produced by the action of various lysophospholipases, including autotaxin (ATX) and phospholipases A1 or A2 (54, 55). Two different LPA species are known, including saturated fatty acids (16:0, 18:0) and unsaturated fatty acids (16:1, 18:1, 18:2, 20:4). In humans, the most abundant form of LPA is 16:0-LPA, followed by 18:2-LPA and 18:1-LPA (56–59). Different LPA types are recognized by different LPA receptors and have different biological activities. LPA mediates its action mainly by activating six known G protein-coupled receptors (GPCRs) (60). In addition, LPA can bind and activate the atypical receptor RAGE (23) and the cation channel transient receptor potential vanilloid 1 (TRPV1) (61). LPA and LPA receptor signaling has been found to be associated with a variety of physiological and pathophysiological conditions, including cancer (62), cardiovascular disease (63), diabetic microvascular complications (64), neuropathic pain (65), etc. RAGE is involved in LPA-induced phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) and activation of extracellular signal-regulated kinases (ERK), among others (23, 66, 67). Although LPA and its interaction with RAGE have been identified, the involvement of LPA-RAGE under different pathophysiological conditions remains to be further explored.

2.5 Aβ

Aβ is a cleaved form of amyloid precursor protein produced by hydrolytic cleavage of proteins and is a major neuropathological marker of Alzheimer’s disease (AD) (68). The two most prevalent forms of Aβ are Aβ1-40 and Aβ1-42, with Aβ1-42 being the most toxic form that accumulates in the brains of AD patients (69). It was shown that RAGE is upregulated in AD and that the V domain of RAGE binds to Aβ oligomers, while the C1 domain of RAGE interacts with Aβ aggregates and is involved in the neurotoxic effects of Aβ in the brain (70). Aβ activation of RAGE induces oxidative stress in neurons and pro-inflammatory cytokine production in microglia by stimulating NADPH oxidase production of reactive oxygen species (71, 72). In addition, RAGE in the endothelium mediates Aβ transport across the blood-brain barrier into the central nervous system, leading to Aβ accumulation in brain tissue and promoting the formation of neuroinflammatory plaques (73). Taken together, Aβ is a potent ligand for RAGE and their binding is involved in the pathophysiological process of the disease, which provides evidence that blocking this interaction may open up new ideas for RAGE-mediated therapy.

2.6 Phosphatidylserine

PS is a negatively charged phospholipid, which is one of the important components of cell membrane phospholipids and has an important role in the regulation of many cellular metabolic processes. PS, a negatively charged phospholipid normally confined to the inner plasma membrane leaflet by flippases, is externalized on the apoptotic cell surface by scramblases, and is an important signal for macrophage recognition and clearance of apoptotic cells (74, 75). PS initiates phagocytic signaling, allowing target cells to be recognized by a wide range of receptors located on the surface of macrophages, including brain-specific angiogenesis inhibitor 1 (BAI-1), T-cell immunoglobulin mucin 4 (TIM-4), stabilin-2, and RAGE (22, 76–78). Under apoptotic conditions, PS binds to RAGE on macrophages leading to activation of Rac1/Cdc42 and ERK and induction of phagocytosis (79). It has been shown that RAGE dysfunction is associated with abnormal alveolar
epithelial remodeling occurring in the pathogenesis of pulmonary fibrosis (80). The specific structural domains of PS interaction with RAGE are currently unknown and the interaction between the two is still under investigation. The molecular mechanism of downstream signaling induced by this interaction needs to be further revealed.

2.7 C1q

C1q is a complement protein assembled from 18 polypeptide chains with a C-terminal spherical head region that mediates recognition of multiple molecular structures and an N-terminal collagen-like tail that mediates immune effector mechanisms (81). C1q is mainly synthesized and secreted in phagocytic cells with a C-terminal spherical head region that mediates recognition of multiple molecular structures and an N-terminal collagen-like tail that mediates immune effector mechanisms. The interaction with RAGE are currently unknown and the molecular mechanism of downstream signaling induced by this interaction needs to be further revealed.

| Ligands | RAGE Binding Domain(s) | References |
|---------|------------------------|------------|
| AGEs    | V domain               | (86)       |
| HMGB1   | V domain               | (36)       |
| S100B   | V domain               | (48)       |
| S100A1  | V domain               | (87)       |
| S100A5  | V domain               | (51)       |
| S100A6  | V,C2 domains           | (88, 89)   |
| S100A9  | V domain               | (90)       |
| S100A12 | V,C1 domains           | (91)       |
| S100A13 | C2 domain              | (92)       |
| S100P   | V domain               | (93)       |
| LPA     | V,C2 domains           | (23)       |
| Aβ oligomers | V domain               | (70)       |
| Aβ aggregates | C1 domain               | (70)       |
hepatocytes, HMGB1 interacts with RAGE to activate the MEK1/2/ERK1/2/JNK pathway and increase type I collagen deposition, promote TGF-β production, and participate in the pathogenesis of liver fibrosis (19). These signaling cascades have been shown to lead to further synthesis of RAGE, which in turn activates more pro-inflammatory factors, thus creating a positive feedback loop to enhance the inflammatory response. In RAGE-mediated cell signaling, the diversity of signaling cascades suggests that different RAGE ligands may induce different signaling pathways (especially in different cell types), thus further increasing the complexity of the RAGE network.

4 RAGE and inflammatory diseases

RAGE and its ligands are associated with a variety of inflammatory diseases and are a major inflammatory driver in their pathogenesis.

4.1 RAGE and diabetes complications

Diabetes is a chronic metabolic disease characterized by hyperglycemia, whose high blood glucose levels lead to the accumulation of AGEs, which accelerates the development of vascular complications, including diabetic nephropathy, retinopathy, peripheral neuropathy and cardiovascular disease (111, 112).

The major microvascular complications of diabetes affect the kidney, retina and peripheral nerves. In studies related to diabetic nephropathy, interaction between AGEs and RAGE on glomerular foot cells increases the expression of acetyl heparinase, which degrades acetyl heparan sulfate in the glomerular basement membrane (GBM) and disrupts the filtration barrier, by activating the NF-κB signaling pathway and plays an important role in diabetic nephropathy. Compared with wild-type mice, RAGE-deficient diabetic mice exhibit slower progression of diabetic nephropathy, less expression of
inflammatory and fibrotic mediators in renal tissues, and greater resistance to renal cell apoptosis (113). In addition, DIAPH1-deficient diabetic mice also exhibited a protective effect on diabetic kidneys compared to diabetic mice expressing DIAPH1, suggesting that DIAPH1 is involved in the pathophysiological processes of diabetic nephropathy (114). In studies related to diabetic retinopathy, RAGE and its ligands AGEs, S100 proteins and HMGB1 were found to be up-regulated in the vitreous and preretinal membranes with proliferative diabetic retinopathy and proliferative vitreoretinal retinopathy (115). HMGB1 interacts with Toll-like receptor 4 (TLR4) and RAGE and activates NF-κB to generate an inflammatory response and disrupt the retinal vascular barrier (116). In diabetic neuropathy, electrophysiological and morphological changes within peripheral nerves and dorsal root ganglia are attenuated in RAGE-deficient diabetic mice compared to wild-type mice. In addition, increased expression of HMGB1 and RAGE in diabetic peripheral neuropathy (117). The interaction analysis using GeneMANIA software suggests that HMGB1-RAGE-DIAPH1 interaction may be critical for the progression of diabetic peripheral neuropathy (103).

Cardiovascular disease is a macrovascular complication of diabetes and a major cause of death in diabetes, and its pathophysiology is the narrowing of the arterial wall due to atherosclerotic lesions. In experiments to validate the role of RAGE in diabetic atherosclerosis, total atherosclerotic plaque area was found to be significantly increased in apolipoprotein E (apoE) knockout diabetic mice compared with non-diabetic apoE-/- mice, whereas plaque accumulation in apoE and RAGE double knockout diabetic mice was not significantly different from non-diabetic apoE-/- mice. In addition, plaque area was further reduced in apoE and RAGE double knockout non-diabetic mice compared with non-diabetic apoE-/- mice, confirming the protective effect of RAGE knockout on the development of atherosclerosis (118). Another study confirmed that sRAGE treatment significantly reduced the size and complexity of atherosclerotic lesions, while a decrease in the expression of pro-inflammatory mediators such as inflammatory cell chemokines (JE-MCP-1 and VCAM-1), Cox-2, and tissue factor was observed (119). Burke et al. performed autopsy and immunohistochemical staining of coronary arteries from diabetic and non-diabetic subjects with sudden cardiac death and found that macrophage plaque area and T-cell infiltration were significantly higher in diabetic subjects than in non-diabetic patients. In addition, RAGE and its ligand S100A12 were expressed in the atherosclerotic plaques of both groups of subjects, but to a significantly higher extent in diabetic than in non-diabetic subjects (120). Mac-1/RAGE interaction mediates the adhesion of leukocytes to endothelial cells, and RAGE is directly involved in leukocyte migration across the vessel wall, promoting inflammatory processes and vascular remodeling, especially accelerating the atherosclerotic process in the diabetic vessel wall (121).

The effects of diabetes on the central nervous system have received increasing attention in recent years. Extensive evidence collected from rodent models of diabetes suggests the presence of electrophysiological abnormalities in the hippocampus and hippocampus-dependent behavioral abnormalities, particularly those related to learning, memory, and cognitive function (122, 123). RAGE has received significant attention in the search for potential mechanisms of diabetes-induced cognitive decompensation. An animal study showed that mice with long-term diabetes (18 to 33 weeks of diabetes) exhibited increased expression of RAGE in neurons and glial cells and showed cognitive dysfunction (124). Streptozotocin-induced wild-type diabetic mice exhibited impaired hippocampal-dependent spatial memory, whereas spatial memory in RAGE knockout diabetic mice was not significantly different from controls, further suggesting that parameters associated with hippocampal-dependent spatial memory are dependent on RAGE expression (125).

4.2 RAGE and neurological diseases

RAGE expression is elevated in many inflammatory neurological diseases, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, myasthenia gravis, and cerebrovascular disease.

4.2.1 RAGE and Alzheimer’s disease

Alzheimer’s disease (AD) is a degenerative disease of the central nervous system characterized by progressive cognitive dysfunction and behavioral impairment, and is the leading cause of dementia (68).

One of the pathological features of AD is the presence of a large number of neuroinflammatory plaques in the cerebral cortex, hippocampus, certain subcortical nuclei and thalamus, with Aβ being the main component of neuroinflammatory plaques. In addition, the presence of AGEs was localized in Aβ plaques. In addition, the presence of AGEs was localized in AD transgenic mice (126, 127). Both Aβ and AGEs are able to bind and activate RAGE signaling and induce the expression of pro-inflammatory cytokines such as TNF-α, IL-6 and macrophage colony-stimulating factor (M-CSF) through a nuclear factor KB (NF-KB)-dependent pathway (128). It was found that RAGE expression was elevated in AD patients and AD transgenic mice (129–132). High expression of RAGE in neurons or microglia of AD mice accelerates the accumulation of Aβ and the formation of neuroinflammatory plaques and exacerbates spatial learning deficits, memory impairment, and neuropathological and biochemical changes (133, 134). Interaction of RAGE with AGEs enhances oxidative stress and exacerbates synaptic dysfunction (135). Deletion of the RAGE gene or blockade of RAGE signaling in neurons or microglia of AD mice attenuates Aβ-induced deterioration, protects spatial learning and memory abilities, and prevents synaptic
4.2.2 RAGE and Parkinson’s disease

Parkinson’s disease (PD) is a neurodegenerative disorder commonly seen in middle-aged and older adults, clinically characterized by resting tremor, bradykinesia, myotonia, and postural balance disturbances. Pathological features of PD include progressive death of nigrostriatal dopaminergic neurons and accumulation of alpha-synuclein-containing Lewy bodies and Lewy synapses in degenerating neurons. The exact etiology of PD remains unclear. There is growing evidence that oxidative stress and inflammatory responses involved in the RAGE process play a crucial role in PD disease progression (105, 145).

It was shown that RAGE was strongly expressed in the substantia nigra and frontal cortex of PD patients as well as in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mouse model (146–148). RAGE is a multi-ligand receptor of the immunoglobulin superfamily, expressed mainly by neurons and microglia, and mediates inflammatory responses by activating multiple signaling pathways. α-synuclein is a central player in causing neuronal cell death in PD, acquiring toxicity mainly through its misfolding or aggregation. It was found that α-synuclein was glycosylated in both PD models and brain tissue of PD patients, and that glycosylation induced α-synuclein oligomerization and stabilization as oligomers, exacerbating its toxic effects (149). Glycosylated α-synuclein and its oligomers activate microglia and induce the release of cytokines and NF-κB signaling proteins by interacting with RAGE, thereby activating signaling cascades in the brain and destroying an increasing number of neuronal cells (150).

Furthermore, in a study of sporadic PD in a group of Chinese Han Chinese population, RAGE -429T/C gene polymorphism was found to be possibly associated with susceptibility to PD (151), suggesting that RAGE may play an important role in the pathogenesis of PD.

The study also found increased expression of S100B and HMGB1 in PD. At pro-inflammatory concentrations, S100B can interact with RAGE to activate the Ras/Rac1-Cdc42/NF-κB and Ras/MEK/ERK1/2/NF-κB pathways to induce microglia activation and release of CCL3, CCL5 and CXCL12 chemokines, exacerbating the inflammatory response (152). HMGB1, one of the RAGE ligands, can also bind to it to produce pathogenic effects (147, 153). In addition, RAGE-deficient mice treated with MPTP had a higher number of surviving dopaminergic neurons compared to their littermate control mice. A recent animal experiment applied lentiviral transfection to silence RAGE expression for the first time to investigate the role of the RAGE signaling pathway in PD, further validating the involvement of RAGE in pro-inflammatory changes during PD in animal models. The results also showed that MAPK/p38 activation mediated the secretion of RAGE-NF-κB-dependent pro-inflammatory cytokines, which induced dopamine degradation in the striatum and loss of tyrosine hydroxylase neurons in the substantia nigra. Reduction of NF-κB translocation to the nucleus by RAGE ablation, accompanied by downregulation of COX2 expression, one of the pro-inflammatory cytokines, ameliorates the RAGE-induced inflammatory response (154).

4.2.3 RAGE and Myasthenia Gravis

Myasthenia gravis (MG) is an antibody-mediated autoimmune inflammatory disease of the neuromuscular junction, characterized by fluctuating skeletal muscle weakness and, in severe cases, life-threatening involvement of respiratory muscles. T cells, B cells, complement and cytokines play a key role in the pathogenic inflammation of MG (155).
The role of RAGE and its ligand S100B has been demonstrated in rats with experimental autoimmune myasthenia gravis (EAMG). In this study, an EAMG model was constructed by immunizing female Lewis rats with an AChR epitope corresponding to amino acids 97-116 of the rat α-subunit. At the late stage of initial immunization, the expression level of RAGE was significantly higher in CD4+ T cells harvested from lymph node mononuclear cells in EAMG rats compared to controls. Furthermore, based on immunohistochemical staining results, RAGE expression was elevated in the spleen of EAMG rats compared to controls, and it was confirmed that activation of RAGE exacerbates EAMG. Administration of RAGE-blocking RAGE-Fc significantly reduced disease severity in EAMG. In addition, serum levels of S100B were elevated in EAMG rats at late initial immunization (45 days) compared to controls and stimulated CD4+ T cell distribution during the EAMG process, and in addition, the interaction of RAGE with S100B upregulated AChR-specific T cell proliferation. The findings suggest that RAGE and its ligand S100B play an important role in EAMG progression by regulating T cell responses and inducing splenocyte-derived AChR-specific antibody production (156). In another study on EAMG rats, EAMG rats with diabetes mellitus showed more symptoms of muscle weakness and poorer clinical scores compared to controls by an unclear mechanism, which was considered to be related to elevated levels of AGEs caused by hyperglycemia, which triggers inflammation by binding to specific receptors, and AGEs induced maturation of dendritic cells (DCs) and enhanced their ability to stimulate T cell proliferation and cytokine production (157).

Moser et al. conducted a cross-sectional study on the role of the RAGE pathway in the pathophysiology of MG, including 42 MG patients and 36 healthy controls (158). It was shown that the levels of soluble receptors sRAGE and esRAGE were significantly lower in MG patients compared to controls, especially in late onset MG (LOMG), and that sRAGE levels did not correlate significantly with drug therapy, clinical manifestations of the disease, or the presence of AChR-specific antibodies. In the same study, correlations were performed for the RAGE ligands HMGB1, S100B, S100A8, and AGE-CML, with no significant differences compared to controls. These results suggest that RAGE may also play a novel role in the pathogenesis and progression of human MG.

The thymus is the site of T cell differentiation, development and maturation, and its role in the pathogenesis of MG is well established. Thymus abnormalities, including thymoma and thymic hyperplasia, are present in about 80% of MG patients. Thymoma is found in about 20-30% of MG patients, and MG is present in about 30-50% of thymoma patients (159). The abnormal immune response in MG patients is closely related to the thymus. Moser et al. investigated the role of RAGE in thymic abnormalities (160) and reported a strong accumulation of RAGE and its ligand HMGB1 in all histological types of thymic epithelial tumors, which was particularly significant in the most aggressive types - thymic carcinoma and B3 thymoma. RAGE expression was elevated in thymocytes, macrophages, Hassall vesicles, thymic medulla and germinal center cells in patients with myasthenia gravis, suggesting that the RAGE pathway may have an impact on the pathogenesis of myasthenia gravis. In another study, thymus specimens from 41 patients with myasthenia gravis (18 thymomas, 17 hyperplasia and 6 other types of pathology) were subjected to RAGE using immunohistochemical methods (161). In agreement with Moser’s findings, RAGE was more significantly expressed in MG combined with thymoma, especially type B2. All of the above findings suggest that the RAGE pathway is involved in the pathophysiological processes of MG, and is more pronounced in MG with thymic abnormalities.

4.2.4 RAGE and Multiple Sclerosis

Multiple sclerosis (MS) is a demyelinating autoimmune disease of the central nervous system. The innate immune system, composed of CNS-resident microglia and infiltrating macrophages, and the adaptive immune system, composed of T lymphocytes and B lymphocytes, play key roles (162).

Previous studies have shown that RAGE and its ligand HMGB1 are highly expressed in active lesions of MS and its corresponding animal model of experimental autoimmune encephalomyelitis (EAE), in which microglia and macrophages are the main sources of HMGB1 in MS and EAE lesions, and that HMGB1 levels correlate with active inflammation. The interaction of HMGB1 with RAGE not only induces the secretion of pro-inflammatory cytokines but also mediates the upregulation of cell adhesion molecules (ICAM-1, VCAM-1 and E-selectin) expression, amplifying the inflammatory response in the pathogenesis of MS and EAE (163, 164).

Immune cells are infiltrated and activated in the CNS, and the metabolic pattern changes from oxidative phosphorylation (OXPHOS) to glycolysis (165, 166). A glycation agent, MGO, is produced during glycolysis, which in turn is derived into AGES that induce an inflammatory response by activating the RAGE pathway. Compared with healthy controls, serum levels of AGES were increased and sRAGE levels were significantly lower in MS patients, and sRAGE serum levels were negatively correlated with the Expanded Disability Status Scale (EDSS) and clinical relapse rates (167). Similarly, esRAGE serum levels correlated with the Multiple Sclerosis Severity Scale (MSSS) and six-month clinical relapse rates. In addition, serum esRAGE levels were significantly higher in MS patients treated with disease-modifying drugs (DMDs) compared with those not treated with DMDs (168). Sternberg et al. found a significant increase in the percentage of RAGE-positive monocytes and T lymphocytes in the peripheral blood of MS patients (169), further supporting the involvement of RAGE in MS pathophysiological processes.
The relevance of RAGE gene polymorphisms in MS patients has been described. In a study of a Hungarian population, significant differences in the distribution of RAGE -374 T/A genotypes were found between controls and MS patients, while no differences were observed between MS patients and controls in the distribution of RAGE -479 T/C and G82S genotypes (170). However, in a Chinese population study, the RAGE G82S gene polymorphism was found to be significantly different in MS patients and healthy controls (171). Although these two studies revealed differences in RAGE gene polymorphisms in MS patients compared to controls, genome-wide association studies were unable to confirm these polymorphisms in a large cohort. These results suggest that RAGE gene polymorphisms may be associated with population differences due to ethnic background, environmental factors, etc.

4.2.5 RAGE and Stroke

Stroke is an acute cerebrovascular disease. It is divided into hemorrhagic stroke and ischemic stroke. Hemorrhagic strokes include cerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH). Inflammatory cells and immune cells are key factors in post-stroke injury. Stroke not only activates inflammatory and immune cells in the central nervous system, but also induces infiltration and accumulation of inflammatory and immune cells in the peripheral system. Both glial cells and peripheral immune cells are involved in regulating the inflammatory response to stroke (172).

RAGE and its ligand HMGB1 are among the factors involved in the inflammatory response in stroke. Elevated levels of HMGB1 were found in the serum of ischemic stroke patients and in the brain tissue of ischemic mice, and inhibition of HMGB1 improved ischemic brain injury in mice (173). In vitro studies showed that RAGE expression in glial cells mediated the toxic effects of HMGB1 (173). Another study found that in a mouse model of ischemic stroke, hyperglycemia increased infarct volume and decreased the number of protective noninflammatory monocytes/macrophages in the ischemic brain compared with controls. This process is mainly mediated by α-dicarbonyl (AGEs precursors) and RAGE (174). In a study on the correlation between early brain injury caused by ICH and RAGE pathways, it was found that RAGE and its ligand HMGB1 expression was increased 12 hours after ICH, along with increased NF-κB p65 expression, increased blood-brain barrier permeability, brain edema, motor dysfunction and nerve fiber damage. In addition, local levels of inflammatory factors IL-1β, IL-6, and IL-8R were also elevated. Inhibition of RAGE expression improved these conditions (175). In conclusion, these findings highlight the role of ligand-RAGE signaling in the pathophysiology of ICH. However, the presence of RAGE is not always detrimental. It was shown that RAGE was upregulated in SAH rats and that the increased RAGE was mainly expressed by neurons and microglia (176). In the treatment of SAH rats with RAGE inhibitors, it was found that inhibition of RAGE significantly reduced brain edema and improved neurological function one day after SAH. However, at three days after SAH, RAGE inhibitor-treated rats exhibited increased neuronal cell death, higher levels of apoptosis and reduced autophagy. These data suggest that, at least in the rat model of SAH, RAGE may exert both destructive and protective effects. This may be based on its role in different cell types and the timing of the post-SAH response (177).

In conclusion, RAGE and its ligands are involved in the inflammatory response to stroke. Blocking effects on the RAGE axis are not always beneficial or detrimental, which emphasizes the possibility that RAGE exerts different effects depending on the cell type acting and the period of stroke. More extensive time-course studies of RAGE and its ligands and further exploration of their role in stroke patients are necessary to provide new ideas for the treatment of stroke.

4.3 RAGE and Cancer

The RAGE signaling pathway is involved in the development of a variety of cancers, including glioma, bladder cancer, breast cancer, melanoma, liver cancer, pancreatic cancer, prostate cancer, colorectal cancer, ovarian cancer, gastric cancer, lung cancer, etc (178–185). Malignant tumor cells as well as multiple cell types within the tumor microenvironment (including fibroblasts, leukocytes and vascular cells) can express and secrete a variety of RAGE ligands. These ligands act synergistically in an autocrine and paracrine manner to control different forms of cellular signaling, including inflammation, proliferation, apoptosis, autophagy and migration, to promote malignant progression of cancer (186, 187). Gene expression analysis of human patients and mouse tumor models revealed overexpression of RAGE and its ligands in a variety of solid tumors. RAGE interferes with apoptosis via a p53-dependent mitochondrial pathway and controls autophagy by decreasing phosphorylation of mammalian target of rapamycin (mTOR), anti-apoptotic proteins, and increasing Beclin-1/VPS34 autophagosome formation (188). Blocking RAGE signaling slows cancer invasion and metastasis in cellular and animal models (3, 110, 179, 189).

RAGE signaling can also influence the malignancy of tumors by acting on the tumor microenvironment. Hypoxia is a prominent feature of the tumor microenvironment. Hypoxia induces RAGE expression in tumor cells, promotes leukocyte recruitment and increases inflammatory stress in the tumor microenvironment, which further enhances tumor cell proliferation, angiogenesis and metastasis (178). Myeloid-derived suppressor cells (MDSC) are an important component of the tumor microenvironment and have the ability to
significantly suppress the immune cell response. They originate from common myeloid primitive cells in the bone marrow, accumulate in response to multiple pro-inflammatory mediators, and are recruited to the tumor microenvironment by chemokines. RAGE contributes to MDSC production and enhances their function (190, 191). Thus, RAGE affects not only tumor cells but also the tumor microenvironment, which is essential for tumor growth, invasion and metastasis. It is a highly researched therapeutic target in cancer.

4.4 RAGE and other inflammatory diseases

The RAGE axis is involved in rheumatoid arthritis (192), systemic lupus erythematosus (193), amyotrophic lateral sclerosis (194), inflammatory bowel disease (195), depression (196) and other diseases. In addition, RAGE is involved in the fibrotic process in several organs, such as hepatic fibrosis (19), cardiac fibrosis (197), pulmonary fibrosis (198) and renal fibrosis (199) (Figure 2).

5 RAGE Inhibitors

Research on RAGE as a target for disease therapy is currently focused on sRAGE, anti-RAGE antibodies and RAGE small molecule inhibitors. According to the difference of RAGE small molecule inhibitors targeting the RAGE region, they are divided into two categories: inhibitors targeting the extracellular segment of RAGE and inhibitors targeting the intracellular segment of RAGE.

5.1 Targeted RAGE extracellular segment inhibitors

5.1.1 TTP488

TTP488, also known as PF-04494700 or azeliragon, is an orally administered small molecule RAGE inhibitor. Preclinical evidence suggests that TTP488 blocks the binding of RAGE to AGEs, HMGB1, S100 proteins and Aβ and improves cognitive function (200). In the clinical phase III trial of TTP488 for AD, there was no significant improvement in cognition or function in...
patients taking TTP488 compared to placebo, and the clinical drug trial ended in failure. However, as a typical RAGE extracellular segment inhibitor, the application of TTP488 in other related diseases and the structural modification and conformational relationship studies based on the existing ones are still valuable to be explored.

5.1.2 FPS-ZM1

FPS-ZM1 is a specific RAGE inhibitor screened from more than 5000 compounds with tertiary amide as the basic pharmacodynamic group. FPS-ZM1 can cross the blood-brain barrier and block the binding of Aβ to RAGE by binding to the V domain of RAGE without interfering with the binding of Aβ to other receptors (201). FPS-ZM1 has been reported to play a potential therapeutic role in a variety of disease models, such as neurodegeneration (202), diabetes (203), cardiovascular disease (204) and cancer (179). In primary cultured rat microglia, FPS-ZM1 significantly inhibits AGEs-induced inflammation and oxidative stress (202). In an in vitro model of murine heart tissue (ECT), FPS-ZM1 partially attenuated the increase in ROS and inflammatory response after prolonged AGEs exposure and rescued ECT function (203). FPS-ZM1 reverses amyloid Medini-induced endothelial dysfunction and oxidative stress in a human umbilical vein endothelial cell model (204). In vitro studies on highly metastatic breast cancer cells showed that FPS-ZM1 eliminated the over-invasion caused by RAGE. In a mouse xenograft model, FPS-ZM1 inhibited primary tumor growth, suppressed tumorangiogenesis and inflammatory cell recruitment, and prevented metastasis to the lung and liver compared to vector-treated controls (179).

5.2 Targeted RAGE intracellular segment inhibitors

Targeting the intracellular segment of RAGE and interfering with ctRAGE-DIAPH1 interaction is a novel mechanism to specifically inhibit RAGE signaling. Recently, Ann Marie Schmidt’s team has developed a small molecule inhibitor called RAGE229 that inhibits the interaction between ctRAGE and DIAPH1, thereby completely inhibiting signaling within RAGE cells (205). In a diabetic mouse model, RAGE229 attenuated short-term and long-term diabetic complications in both male and female mice without reducing blood glucose concentrations. RAGE229 treatment reduced plasma concentrations of TNF-α, IL-6 and CCL2/JE-MCP1 in diabetic mice, while reducing pathological and functional indicators of diabetic-like nephropathy. As a novel small molecule inhibitor targeting protein interactions, RAGE229 is expected to be used for the treatment of short-term and long-term complications caused by diabetes.

6 Summary and prospect

RAGE is expressed at low levels under normal physiological conditions, but under chronic and persistent inflammatory conditions, RAGE signaling is upregulated and involved in the development of multiple diseases. Targeting RAGE appears to be a promising therapeutic strategy to control RAGE-mediated diseases. Several approaches to block RAGE signaling have been proposed and are being investigated, however, most are in preclinical studies and further human clinical trials need to be implemented to validate their safety and efficacy for the treatment of multiple RAGE-related diseases. In addition, because RAGE also has an important role under normal physiological conditions, future studies need to have a better understanding of the advantages and disadvantages of RAGE-targeted therapies and the long-term effects of RAGE blockade in humans before possible targeted RAGE therapeutic strategies can be established.

Author contributions

HaD contributed to conception, design and drafted the manuscript. YZ collected the data and designed the figures. YH performed literature search, and provided valuable comments. HuD performed manuscript review and final version approval. All authors contributed to the article and approved the submitted version.

Acknowledgments

We wish to thank Figdraw platform for providing the graphic materials.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Cancer. Clin Chim Acta advanced glycation end products in mice. High mobility group box-1 drives repair. Dong et al. 10.3389/FrontImmunol.2020.39(11):e103477. doi:10.15252/embj.2019103477 association with diabetic retinopathy. and a notch homolog, human counterpart of mouse mammary tumor gene int-3. gene for receptor of advanced glycation end products, PBX2 homeobox gene signaling in renal tubular epithelial cells. induced alveolar epithelial to mesenchymal transition. 10.1016/j.bbadis.2014.06.017 A novel receptor-mediated mechanism for myocyte apoptosis postinfarction. S100B interaction with the receptor for advanced glycation end products (RAGE): 10.1080/14789450.2018.1536551 advanced glycation end products (RAGE) and DIAPH1: Unique mechanisms and Rep. Disord Drug Targets role of HMGB1 in development and arthritis: The G82S polymorphism ampli- fies the in... RAGE: A single receptor – Trends Biochem Sci (1973) 8(12):14–9. doi:10.1016/0033-8584(73)90119-5. References 21. Palanissami G, Paul SFD. RAGE and its ligands: Molecular interplay 19. Ge X, Arriazu E, Magdaleno F, Antoine DJ, Dela Cruz R, Theise N, et al. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required... 23. Rai V, Toure F, Chitayat S, Pei R, Song F, Li Q, et al. Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling. J Exp Med (2012) 209(13):2339–50. doi:10.1084/jem.20120873 24. Ma W, Rai V, Hudson BI, Song F, Schmidt AM, Barile GR. RAGE binds Cq and enhances Cq-mediated phagocytosis. Cell Immunol (2012) 274(1-2):72–82. doi:10.1016/j.cellimm.2012.02.001 25. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem (1992) 267(21):14988–5004. doi:10.1002/jbc.267149888 26. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation (2006) 114(6):597–605. doi:10.1161/CIRCULATIONAHA.106.621854 27. Carimi C, Founds H, Nicholl I, Mitsubishi T, Giordano D, Vanpatten S, et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci USA (1997) 94(25):13915–20. doi:10.1073/pnas.94.25.13915 28. Hanssen NM, Stohsower CDA, Schalkwijk CG. Myelinolysis stress, the glycokine system, and diabetic chronic kidney disease. Curr Open Nephrol Hypertens (2019) 28(1):26–30. doi:10.1007/s12672-018-0342-9 29. Luzvano-Contreras C, Chapman-Novakofski K. Dietary advanced glycation end products and aging. Nutrients (2010) 2(12):1247–65. doi:10.3970/nutrients.212247 30. Poulsen MW, Hedegaard RV, Andersen JM, de Courten B, Bugel S, Nielsen J, et al. Advanced glycation endproducts in food and their effects on health. Food Chem Toxicol (2013) 60:10–37. doi:10.1016/j.fct.2013.06.052 31. Nowotny K, Jung T, Hohn A, Weber D, Grune T. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules (2015) 5(1):194–222. doi:10.3390/biom5010194 32. Fukami K, Yamagishi S, Okuda S. Role of AGEs-RAGE system in cardiovascular disease. Curr Pharm Des (2014) 20(14):2395–402. doi:10.2174/1567205043480582 33. Takeuchi M, Kikuchi S, Sasaki N, Suzuki T, Watai T, Iwaki M, et al. Involvement of advanced glycation endproducts (AGEs) in alzheimer’s disease. Curr Alzheimer Res (2004) 1(1):39–46. doi:10.2174/1567205043480582 34. Daryia B, Nagaraju GP. Advanced glycation end products in diabetes, cancer and phytochemical therapy. Drug Discov Today (2020) 25(9):1614–23. doi:10.1016/j.drudis.2020.07.003 35. Ashraf MJ, Ahmad S, Choi I, Ahmad N, Farhlan M, Tataya G, et al. Recent advances in detection of AGEs: Immunological, biochemical and bioinformatic approaches. HumMB Life Sci (2015) 67(12):897–913. doi:10.1002/ibmb.1450 36. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, et al. The receptor for advanced glycosylation end products (RAGE) is a cellular binding site for amphoterin. Gene. 1994;20(13):323–35. doi:10.1038/363861 37. Pietrocola F, Lapolla A, Ragazzi E, Sasina A, Sechi A, Nollino L, et al. Role of endogenous secretory RAGE (esRAGE) in defending against plaque formation induced by oxidative stress in type 2 diabetic patients. Atherosclerosis (2013) 226(1):252–7. doi:10.1016/j.atherosclerosis.2012.10.050 38. Hudson BI, Lippman ME. Targeting RAGE signaling in inflammatory disease. Am J Respir Cell Mol Biol (2018) 69:348–64. doi:10.1165/amjrcmb.2018-036514 39. Kumar V, Agrawal R, Pandey A, Kopf S, Hoeffgen M, Kaymak S, et al. Compromised diabetes repair is responsible for diabetes-associated fibrosis. EMBO J (2020) 39(11):e103477. doi:10.15252/embj.2019103477 40. Kumar V, Fleming T, Teyjung S, Gorzelanny C, Gebhardt C, Agrawal R, et al. Homostatic nuclear RAGE-ATM interaction is essential for efficient DNA repair. Nucleic Acids Res (2017) 45(18):10595–613. doi:10.1093/nar/gkx1075 41. Ge X, Arriazu E, Magdaleno F, Antoine DJ, Dela Cruz R, Theise N, et al. High mobility group box-1 drives fibrosis progression signaling via the receptor for advanced glycosylation end products and mice. Hepatology (2018) 68(2):2388–404. doi:10.1002/hep.30903 42. Xiao X, Yang C, Qu SL, Shao YD, Zhou CY, Cao R, et al. ST00 proteins in atherosclerosis. Clin Chim Acta (2020) 502:293–304. doi:10.1016/j.clincha.2019.11.019 43. Palaniyasm G, Paul SFD. RAGE and its ligands: Molecular interplay between glycation, inflammation, and hallmarks of cancer-a review. Hema Cancer (2018) 9(5):295–325. doi:10.1186/s12672-018-0342-9 44. He M, Kubo H, Morimoto K, Fujino N, Suzuki T, Takahasi T, et al. Receptor for advanced glycation end products binds to phosphatidylserine and assists in the clearance of apoptotic cells. EMBO Rep (2011) 12(4):358–64. doi:10.1038/embor.2011.28 45. Rai V, Toure F, Chitayat S, Pei R, Song F, Li Q, et al. Lysophosphatic acid targets vascular and oncogenic pathways via RAGE signaling. J Exp Med (2012) 209(13):2339–50. doi:10.1084/jem.20120873 46. Ma W, Rai V, Hudson BI, Song F, Schmidt AM, Barile GR. RAGE binds Cq and enhances Cq-mediated phagocytosis. Cell Immunol (2012) 274(1-2):72–82. doi:10.1016/j.cellimm.2012.02.001 47. Massey CA, Dejana E, Alexander S, Davey N. The role of HMGB1 in cancer and the immune system. Cytokine Growth Factor Rev (2006) 17(3):189–201. doi:10.1016/j.crgfr.2006.01.003 48. Kwik MS, Kim HS, Lee B, Kim YH, Son M, Shin JS. Immunological significance of HMGB1 post-translational modification and redox biology. Front Immunol (2020) 11:1889. doi:10.3389/fimmu.2020.01189 49. Urbanovacite V, Volle RE. High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus. J Intern Med (2011) 270(4):309–18. doi:10.1111/j.1365-2796.2011.02422.x 50. Scaffidi P, Mustici T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature (2002) 418(6894):191–5. doi:10.1038/nature01085 51. Dong et al. 10.3389/fimmu.2022.931473
unsaturated lysophosphatidic acids. Circ Res et al. Phenotypic modulation of vascular smooth muscle cells induced by lysophosphatidic acid in human blood fractions. hh1501.094265

Cancer and -independent interactions of the S100 protein family. amyloid self-assembly of S100 proteins: structural basis of functional diversity. EMBO J 2007 26(16):3868–78. doi: 10.1038/sj.emboj.7601805

lysophosphatidic acid production. doi: 10.1016/j.bbalip.2008.06.005

RAGE: An update. lysophosphatidic acid mediates lysophosphatidic acid transcytosis through the blood-brain barrier and accumulation in brain. Nat Med (2003) 9(7):907–13. doi: 10.1038/nm890

Askarova Y, Yang X, Sheng W, Sun GY, Lee JC. Role of abeta receptor for advanced glycation endproducts interaction in oxidative stress and cytosolic phospholipase A2(1) activation in astrocytes and cerebral endothelial cells. Neuroscience (2011) 199:375–85. doi: 10.1016/j.neuroscience.2011.09.038

Deane R, Du Yan S, Subramaniam RK, LaRue B, Jovanovic S, Hogg E, et al. RAGE mediates lysophosphatidic acid transcytosis through the blood-brain barrier and accumulation in brain. Nat Med (2003) 9(7):907–13. doi: 10.1038/nm890

Segawa K, Nagata S. An apoptotic ‘eat me’ signal: Phosphatidylserine exposure. Trends Cell Biol (2015) 25(11):69–50. doi: 10.1016/j.tcb.2015.03.017

Murphy JE, Tacon D, Tedbury PR, Hadden JM, Knowling S, Sawama T, et al. LOX-1 scavenger receptor mediates calcium-dependent recognition of phosphatidylserine and apoptotic cells. Biochem J (2006) 396(2):201–14. doi:10.1042/BJ20060195

Leclerc E, Fritz G, Vetter SW, Heizmann CW. Binding of S100 proteins to phosphatidylserine and apoptotic cells. FEBS J (2006) 272(24):4758–90. doi:10.1111/j.1742-4658.2010.07887.x

Santamaria-Kiesel L, Rintala-Dempsey AG, Shaw GS. Calcium-dependent and -independent interactions of the S100 protein family. Biochem J (2006) 396(2):201–14. doi:10.1042/BJ20060195

Leecler E, Fritz G, Vetter SW, Heiizmann CW. Binding of S100 proteins to phosphatidylserine and apoptotic cells. FEBS J (2006) 272(24):4758–90. doi:10.1111/j.1742-4658.2010.07887.x

Cristeofs J, Gomes CM. S100i proteins in alzheimer’s disease. Front Neurosci (2019) 13:463. doi:10.3389/fnins.2019.00463

Bresnick AR, Weber DJ, Zimmer DB. S100 proteins in cancer. J Biochem (2003) 108(14):1746–53. doi:10.1093/jb/mvg052

Yoshida K, Nishida W, Hayashi K, Ohkawa Y, Ogawa A, Aoki J, et al. Vascular remodeling induced by naturally occurring unaturated lysophosphatidic acid in vivo. Circulation (2003) 108(14):1746–52. doi:10.1161/01.CIR.0000089734.35455.F3

Aoki J, Inoue A, Okudaira S. Two pathways for calcium-dependent and -independent interactions of the S100 protein family. Biochem J (2006) 396(2):201–14. doi:10.1042/BJ20060195

Ostendorp T, Leclerc E, Galichet A, Koch M, Demling N, Weigle B, et al. Structural and functional insights into RAGE activation by multimeric S10B8. EMBO J (2007) 26(16):3868–78. doi: 10.1038/sj.emboj.7601805

Fitz G, Botelho HM, Morovou-Roche LA, Gomes CM. Natural and amyloid assembly of S100 proteins: structural basis of functional diversity. FEBs J (2010) 277(22):4578–90. doi: 10.1111/j.e.1742-4658.2010.07887.x

Wilson NC, Tevethia JS. Structure of the RAGE:S100A6 complex reveals a unique mode of function of the receptor for advanced glycation end products (RAGE). Cell Death Differ (2001) 8(1):81–8. doi:10.1038/sj.bdd.4400755

Yamai H, Ban T, Wang Z, Choi MK, Kawamura T, Negishi H, et al. HMGB1 is an LPA producing enzyme with function of C1q receptors and C1q binding proteins at the cell surface. Immunobiology (2011) 216(9):1128–36. doi:10.1016/j.imbio.2010.11.013

Freeman GJ, Casasnovas JM, Umetu DT, DeKruyff RH. TIM genes: A cell surface family of phagocytosis-mediating receptors that regulate innate and adaptive immunity. Immunol Rev (2016) 213(1):172–89. doi:10.1111/imr.12600

Park D, Tosolli-Trampont AC, Elliott MR, Lu M, Haney LB, Ma Z, et al. BA1H is an engulfment receptor for apoptotic cells upstream of the ELMO/C1q receptor. Cell Death Differ (2015) 22(1):78–85. doi:10.1038/cdd.2014.33

Twichell E, Galichet A, Weibel M, Leclerc E, Heizmann CW. Site-specific blockade of RAGE-dependent lysophosphatidic acid signalling in mouse sensory neurons. Neurobiology (2008) 28(2):514–59. doi:10.1016/j.neuroscience.2007.08.003

Kandarpa A, van der Vies SM, Rozenmuller AJ, van Horsen J, de Vries HE. Amyloid beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxid Redox Signal (2011) 15(5):1677–82. doi:10.1089/ars.2011.3895
Change in the molecular dimension of a RAGE-ligand complex triggers advanced glycation end product-induced endothelial hyperpermeability. Cell 111.262519

Circ Res mediates vascular remodeling of ERK1/2-NF-κB and JNK-AP-1 signaling pathways. Korkolopoulou P, et al. Advanced glycation end products upregulate lysyl oxidase and endothelin-1 in human aortic endothelial cells: potential contributions to disease. jbc.M110.117457

doi: 10.1128/MCB.24.11.4880-4894.2004

Impairment in entorhinal cortex. Stimulation of myogenesis and counteracts the antimyogenic factors basic fibroblast growth factor and S100B via RAGE binding. Mol Cell Biol (2004) 24(11):4880–94. doi: 10.1128/MCB.24.11.4880-4894.2004
Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation. 

Chem (1995) 270(9):4854

like tau pathology and memory deficits. 

J. Neurobiol Aging. 2007.03.012

glycogen synthase kinase-3 inhibits protein phosphatase-2A and the underlying mechanisms. 

Hum Mol Genet (2008) 17(9):1348–55. doi: 10.1093/hmg/ddy017

Derk J, Bermudez Hernandez K, Rodriguez M, He M, Koh H, Abedini A, et al. Duphanolans 1 (DIAPIH) is highly expressed in the aged human medial temporal cortex and upregulated in myeloid cells during Alzheimer's disease. 

J Alzheimers Dis (2018) 66(3):995–1007. doi: 10.3233/JAD-180088

Emanuele E, D'Angelo A, Tomaino C, Binetti G, Ghidoni R, Politi P, et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease with mild dementia. 

Arch Neurol (2005) 62(11):1734–1740. doi: 10.1001/archneur.62.11.1734

Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, et al. Expression of RAGE and HMGB1 in thymic epithelial tumors, thymic hyperplasia and regular thymic morphology. 

Neurobiol Aging (2011) 32(5):763–77. doi: 10.1016/j.neurobiolaging.2009.04.016

Arancio O, Zhang HP, Chen X, Lin C, Trinchese F, Puzzo D, et al. RAGE potentiates abeta-induced perturbation of neuronal function in transgenic mice. 

EMBO J (2004) 23(20):4906–105. doi: 10.1093/emboj/dmh00415

Fang F, Lue LF, Yan S, Xu H, Luddy JS, Chen D, et al. RAGE-dependent signaling in microglia contributes to neuroinflammation, abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. 

FASEB J (2010) 24(1):1043–55. doi: 10.1096/fj.09-139684

Zhang H, Wang Y, Yan S, Du F, Wu L, Yan S, et al. Genetic deficiency of neuronal RAGE protects against Aβ-induced synaptic damage. 

Cell Death Dis (2014) 5:e1288. doi:10.1038/cddis.2014.248

Mu L, Zhang Y, Sun B, Wang J, Xie X, Li N, et al. Activation of the receptor for advanced glycation end products (RAGE) exacerbates experimental autoimmune myasthenia gravis symptoms. 

Clin Immunol (2011) 141(3):36–48. doi: 10.1016/j.clim.2011.04.013

Zhang P, Yang CL, Du T, Liu YD, Ge MR, Li H, et al. Diabetes mellitus exacerbates experimental autoimmune myasthenia gravis by modulating both adaptive and innate immunity. 

J Neuroimmunol (2018) 1(214). doi: 10.1016/j.jneuroim.2017.02.022

Moser B, Bekos C, Zimprich F, Nickl S, Klepetko W, Ankersmit J. The receptor for advanced glycation end products and its ligands in patients with myasthenia gravis. 

Biochim Biophys Res Commun (2012) 420(1):98–101. doi: 10.1016/j.bbrc.2012.02.121

Menon D, Katzberg H, Barnett C, Pal P, Resjak A, Keshayee S, et al. Thymoma pathology and myasthenia gravis outcomes. 

Muscle Nerve (2021) 63(6):686–73. doi: 10.1002/mus.27220

Moser B, Janik S, Schaefer AI, Mullauer L, Bekos C, Scharrer A, et al. Expression of RAGE and HMGB1 in thymic epithelial thymuses, thymic hyperplasia and regular thymic morphology. 

PLoS One (2014) 9(4):e94118. doi: 10.1371/journal.pone.0094118

Bouchikhi M, Zouaouda F, Benhaddou EHA, Mahassini N, Achir A, El-Malki H. Expression of receptor for advanced glycation end products (RAGE) in thymus from myasthenia patients. 

Rev Neurol (Paris) (2017) 173(6):388–95. doi: 10.1016/j.neurol.2017.03.020

Yamou Bl, Alroughani R. Multiple sclerosis. 

Semin Neurol (2018) 38(2):212–25. doi: 10.1055/s-0038-1649502

Andersson A, Covacu R, Sunnemark D, Danilov AI, Dal Bianco A, Khademi M, et al. Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. 

J Leukoc Biol (2008) 84(5):1248–55. doi: 10.1189/jlb.0408344

Zhang B, Sternberg Z, Bruck S, Trinchese F, Wei C, Chen B, et al. High-mobility group box 1 in multiple sclerosis. 

Immunol Res (2016) 64(3):342–50. doi: 10.1007/s12031-018-1173-4

Sternberg Z, Sternberg D, Chichelli T, Drake A, Patel N, Kolb C, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. 

Cell (2013) 153(6):1239–51. doi: 10.1016/j.cell.2013.05.016

Viola A, Munari F, Sanchez-Rodriguez R, Scalora T, Castegna A. The metabolic signature of macrophage responses. 

Front Immunol (2019) 10.1462. doi: 10.3389/fimmu.2019.01462

Zhang B, Sternberg Z, Bruck S, Chichelli T, Yu J, Hojnacki D, et al. Disease modifying drugs modulate endogenous secretory receptor for advanced glycation end-products, a new biomarker of clinical relapse in multiple sclerosis. 

J Neuroimmunol (2014) 274(1–2):197–201. doi: 10.1016/j.jneuroim.2014.07.005

Sternberg Z, Chioatti A, Tario J, Chichelli T, Patel N, Chada K, et al. Reduced expression of membrane-bound (m)RAGE is a biomarker of multiple sclerosis disease progression. 

Immunobiology (2016) 221(2):193–8. doi: 10.1016/j.imbio.2015.09.007

Tudalescu V, Gryulai Z, Bencsik K, Soltzki Z, Kocsis AK, Somogyvari F, et al. RAGE gene polymorphisms in patients with multiple sclerosis. 

J Mol Neurosci (2009) 39(3):360–5. doi: 10.1007/s12031-009-9291-7

Li K, Zhao B, Dai D, Yao S, Liang W, Yao L, et al. A functional p.82G→S polymorphism in the RAGE gene is associated with multiple sclerosis in the Chinese population. 

Multifurcter (2011) 17(8):914–21. doi: 10.1177/ 1352458511430539

An LY, Yang Y, Zhou L, Li CY, Li WT, Fang WR, et al. Immune cells after ischemic stroke onset: Roles, migration, and target intervention. 

J Mol Neurosci (2018) 66(3):342–55. doi: 10.1007/s12031-018-1173-4
RAGE and its ligand HMGB1, and prognosis and pathogenesis of gastric cancer. \( \text{J Neurosci} \) (2016) 36(36):9313-25. doi: 10.1523/JNEUROSCI.0473-16.2016

140. Wang F, Wang Z, Zhang JH, Tang J, Liu X, Tan L, et al. Receptor for advanced glycation end-product antagonist reduces blood-brain barrier damage after intracerebral hemorrhage. \( \text{Stroke} \) (2015) 46(5):1328-36. doi: 10.1161/STROKEAHA.114.003834

141. Li H, Wu W, Sun Q, Liu M, Li W, Zhang XS, et al. Expression and cell distribution of receptor for advanced glycation end-products in the rat cortex following experimental subarachnoid hemorrhage. \( \text{Brain Res} \) (2014) 1543:315-23. doi: 10.1016/j.brainres.2013.11.023

142. Li H, Yu SJ, Zhang DD, Yang YQ, Huang LT, Yu Z, et al. Inhibition of the receptor for advanced glycation end products (RAGE) attenuates neuroinflammation while sensitizing cortical neurons towards death in experimental subarachnoid hemorrhage. Mol Neurobiol (2017) 54(1):755-67. doi: 10.1007/s12035-016-9703-y

143. Kang R, Hou W, Zhang Q, Chen R, Lee YJ, Bartlett DL, et al. RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer. Cell Death Dis (2014) 5:e1480. doi: 10.1038/cddis.2014.445

144. Kwak T, Drews-Elger K, Ergonul A, Miller PC, Braley A, Hwang GH, et al. Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis. Oncogene (2017) 36(11):1559-72. doi: 10.1038/onc.2016.324

145. Olabas OT, Kadassah S, Vetter SW, Leclerc E. RAGE signaling in melanoma tumors. Int J Mol Sci (2020) 21(23):8999. doi: 10.3390/ijms21238999

146. Zha C, Meng X, Li L, Mi S, Qian D, Li Z, et al. Neutrophil extracellular traps mediate the crosstalk between glioma progression and the tumor microenvironment via the HMGB1/RAGE/IL-8 axis. Cancer Biol Med (2020) 17(1):154-68. doi: 10.20892/j.issn.2095-3941.2019.0353

147. Qian F, Xiao J, Gai L, Zhu J. HMGB1-RAGE signaling facilitates ras-associated diabetes in mice. Int J Mol Sci (2019) 20(2):411. doi: 10.3390/ijms20020411

148. Zhou Y, Liu SX, Zhou YN, Wang J, Ji R. Research on the relationship between RAGE and its ligand HMGB1, and prognosis and pathogenesis of gastric cancer with diabetes mellitus. Eur Rev Med Pharmacol Sci (2021) 25(3):1339-50. doi: 10.26355/erem.s202102.24841

149. Kolonin MG, Sergeeva A, Stauquicini DI, Smith TL, Tarleton CA, Moldrem JJ, et al. Interaction between tumor cell surface receptor RAGE and proteinase 3 mediates prostate cancer metastasis to bone. Cancer Res (2017) 77(12):3144-50. doi: 10.1158/0008-5472.CAN-16-0708

150. Liu Q, Huo W, Zheng H, Zhao J, Jia L, Wang P. Ethyl pyruvate suppresses the growth, invasion and migration and induces the apoptosis of nonsmall cell lung cancer cells via the HMGB1/RAGE axis and the NFκB/STAT3 pathway. Cancer Biol Med (2020) 17(4):154-68. doi: 10.20892/j.issn.2095-3941.2019.0353

151. El-Far AH, Sroga G, Jaouini SKA, Mouna SA. Role and mechanisms of RAGE-ligand complexes and RAGE-inhibitors in cancer progression. Int J Mol Sci (2020) 21(10):3613. doi: 10.3390/ijms21103613

152. Kang R, Tang D, Schapiro NE, Livesey KM, Farkas A, Loughran P, et al. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ (2010) 17(4):666-76. doi: 10.1038/cdd.2009.149

153. Kalaë AZ, See F, Harja E, Arriero M, Schmidt AM, Hudson BJ. Alternatively spliced RAGEVII inhibits tumorigenesis through suppression of JNK signaling. Cancer Res (2010) 70(13):5628-38. doi: 10.1158/0008-5472.CAN-10-0959

154. Wuren T, Huestedtstad T, Beck E, Warren K, Hoodal J, Ostrand-Rosenberg S, et al. The receptor for advanced glycation end products (RAGE) decreases survival of tumor-bearing mice by enhancing the generation of lung metastasis-associated myeloid-derived suppressor cells. Cell Immunol (2021) 365:104379. doi: 10.1016/j.cellimm.2021.104379

155. Ostrand-Rosenberg S, Beury DW, Parker KH, Horn LA. Survival of the fittest: how myeloid-derived suppressor cells survive in the inhospitable tumor microenvironment. Cancer Immunol Immunother (2020) 69(2):215-21. doi: 10.1007/s00262-019-02388-8

156. Monu, Agnihotri P, Saqib M, Sarkar A, Chakraborty D, Kumar U, et al. Translaminin and receptor for advanced glycation end product's differential levels associated with the pathogenesis of rheumatoid arthritis. J Inflammation Res (2021) 14:5581-96. doi: 10.2147/JIR.S27736

157. Nowak A, Przyswara-Chowaniec B, Damasiewicz-Bodzak A, Blachut D, Nowalany-Kozielska E, Ty nghịen-Golder K, Advanced glycation end products (AGEs) and their soluble receptor RAGE in women suffering from systemic lupus erythematosus (SLE). Cells (2021) 10(12):3523. doi: 10.3390/ cells10123523

158. Arab HH, Al-Shorbagy MY, Saad MA. Activation of autophagy and suppression of apoptosis by dasagliloxin attenuates experimental inflammatory bowel disease in rats. Targeting AMPK/mTOR, HMGB1- RAGE and NrTf/HO-1 pathways. Chem Biol Interact (2021) 351:109568. doi: 10.1016/j.cbi.2021.109568

159. Yan W, Xie L, Li Y, Zeng T, Zhao D, Lai Y, et al. Combined rs-fMRI study on brain functional imaging and mechanism of RAGE-DAMPs of depression: Evidence from MDD patients to chronic stress-induced depression models in cynomolgus monkeys and mice. Clin Transl Med (2021) 11(10):e541. doi: 10.1038/s41371-021-00750-4

160. Perkins TN, Oury TD. The perplexing role of RAGE in pulmonary fibrosis causality or casualty? Thorax Respir Dis (2021) 15:7153666210160671. doi: 10.1177/15373502211016071

161. Tammaro A, Florquin S, Brok M, Claessen N, Butter LM, Teske GJ, et al. S100A8/A9 promotes parenchymal damage and renal fibrosis in obstructive nephropathy. Clin Exp Immunol (2018) 193(3):361-75. doi: 10.1111/cei.13154

162. Burstein AH, Sabagh M, Andrews R, Valcarce C, Dunn I, Altstiel L. Development of azeliragon, an orally active small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild Alzheimer’s disease. J Prev Alzheimers Dis (2018) 5(2):149-54. doi: 10.14283/jpad.2018.18

163. Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, et al. A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer and renal fibrosis in obstructive nephropathy. Frontiers in Immunology (2021) 12:450. doi: 10.3389/fimmu.2021.64019

164. Migrino RQ, Davies HA, Truran S, Karamanova N, Franco DA, Beach TG, et al. Amyloidogenic medin induces endothelial dysfunction and vascular inflammation through the receptor for advanced glycation end products. Cardiovasc Res (2017) 113(11):1389-402. doi: 10.1093/cvr/cvx135

165. Manigrasso MB, Rabbani P, Egana-Gorrono L, Quadri N, Frye L, Zhou B, et al. Small-molecule antagonism of the interaction of the RAGE cytoplasmic domain with DIAPH1 reduces diabetic complications in mice. Sci Transl Med (2021) 13(621):eabf7084. doi: 10.1126/scitranslmed.abf7084